Bruce Power & Isogen Explore Production of Yttrium-90 with New Isotope System

The two companies recently announced the launch of a Global Expressions of Interest Process for radiopharmaceutical organizations interested in locating in Ontario for isotope production.

 

Bruce Power announced that building on the success of the new Isotope Production System install in its Unit 7 reactor, it and Isogen, are examining the feasibility of producing yttrium-90, used as a targeted liver cancer therapy.

Peter McDermid, Director of Isotopes and Site Energy Development says that the ability to irradiate medical isotopes presents a great opportunity for the world medical community and they are excited about doing their part to in helping to save lives.

President of Isogen, John D’Angelo says that Yttrium-90 is a promising medical isitope with a growing market and it represents a local next step for the expansion of their isotope production technology.

The two companies recently announced the launch of a Global Expressions of Interest Process for radiopharmaceutical organizations interested in locating in Ontario for isotope production.

The process is set to run until mid-2023.